Member Info for B2HS2L

Bells, presumably there is the option to pay % shares, and % cash.

From RNS 21.10.2024

"Avacta has recently expanded its pre|CISION® platform with the addition of two new preclinical programs: AVA6103 and AVA7100.

AVA6103 is a novel pre|CISION®-enabled peptide drug conjugate comprising exatecan, a potent topoisomerase I inhibitor, designed to deliver its powerful anti-tumor effects directly to the tumor while minimizing exposure to healthy tissues.

AVA7100 is a first-in-class Affimer® drug conjugate, aimed at cancers with varying levels of FAP expression, including low FAP.

Together, these programs reflect the versatility of the pre|CISION® platform and its potential to address a broad range of cancer indications."

For me this is Avacta's statement of intent, which the company will repeat when attempts to value the company are computed, should a predator attempt to swallow Avacta.

So the Affimer part of AVA7100 development very much of value at that point - bringing Affimer IP front and centre - especially where low FAP cancer therapeutics in discussion.

'What ‘object’ removed from the company?'

Transcript of Shareholdeer meeting London 27.06.24

[01:33:59.230]-Christina Coughlin

"....Wetherby was essentially Avacta’s therapeutics, it did hold one key piece of IP, which is the use of that affirmer and antibody link within a diagnostic. We actually just had an IP meeting last night, to be honest with you. And this is what one of the questions is, where does that IP go? As you saw in the RNS, that is with Coris right now. They are the company that we purchased. The goal was to implement the Affimer IP lateral flow test. We can go into it upstairs if anyone would like to. But that is a attractive entity, Coris. And then when you look at Launch, it is a cash generative business. So both successful businesses and one that we've added IP, both have gone through their growth pattern that we set out. We've owned Coris for a year. We've owned Launch since October of 2022. Both have made gains, and yes, we believe we're an attractive entity. We're in that process, so I can't really say any more than that right now."

Could this jigsaw piece be the one being manipulated?

Issued by the American Cancer Society.

07.11.2024 - https://www.cancer.org/content/dam/CRC/PDF/Public/8581.00.pdf

Page 104 - Treatment of Triple-negative Breast Cancer.

For those wishing to bookmark the subject, a good overview IMO.

Note the FWIW part of the response, I don't mind if posters agree or not.

You and your confederates are all about obfuscation wyndrum, hence all the questions.

I never expected there to be an indication of which prospective partners, that would be a very big security problem.

But partners there will have to be, with our finances insufficient to meet the needs of R&D development and trials finances.

FWIW my money is on a new CFO from an unannounced as yet partner.

An ideas man who will have the partners' and Avactas' aims crystal clear.

Four question marks wyndrum, - no chance of you turning over a new leaf in 2025, more's the pity.

FWIW I think it's because we had TG in the CFO role that our need is so great.

A no ideas man if ever there was one.

Raise last Feb a case in point.

Gmcc - 'Asset IP value is currently understated' - Agreed.

Asset IP value is dependent upon our R&D wanting to know anything and everything about the subject of FAP, and to become subject matter leaders.

If so we can assume many more near term IP applications, thus increasing the value of the company short / medium term, building to a great negotiating platform, should BP wish to open T/O negotiations at some future time.

Lets hope so before too long.

You can't have a situation where a company is trying to prove concept, and FDA unofficially agrees.

Successful completion of phase 1a presumably amounts to FDA agreeing proof of concept.

Likewise First in Human trial success is also agreed as safety is proven.

If proof of concept is clear for FDA, then won't a company with a short IP left on their drug want to contract Avacta to use preCISION to deliver their drug, thus resetting their IP time period?

A phase 1b trial not be applicable for an approved drug.

The IP owner just needs to deliver it in a new way, or have I not understood correctly?

Wyndrum - 'sometimes you lot just want to argue for the sake of it.'

That is something else coming from you.

You've wasted whole weekends boring us stupid

Https://clinicaltrials.gov/study/NCT04969835?tab=history&a=8#version-content-panel

Primary Outcome Measures

5 Cardiac safety

Clinically significant reduction in LVEF (fallen by > 10% to below the lower level of institutional normal (as assessed by ECHO).

What's ECHO?

https://www.nhs.uk/conditions/echocardiogram/

Echocardiogram

An echocardiogram, or "echo", is a scan used to look at the heart and nearby blood vessels.

It's a type of ultrasound scan, which means a small probe is used to send out high-frequency sound waves that create echoes when they bounce off different parts of the body.

These echoes are picked up by the probe and turned into a moving image on a monitor while the scan is carried out.

An echocardiogram may be requested by a heart specialist (cardiologist) or any doctor who thinks you might have a problem with your heart, including your GP.

The test will usually be carried out at a hospital or clinic by a cardiologist, cardiac physiologist, or a trained technician called a sonographer.

Although it has a similar name, an echocardiogram is not the same as an electrocardiogram (ECG), which is a test used to check your heart's rhythm and electrical activity.

Https://www.targetedonc.com/view/dr-christopher-twelves-on-the-rising-issue-of-metastatic-breast-cancer

Unfortunately I don't think therapeutics have moved on for breast cancer care since his 2016 speech.

We can only hope Avacta make up for lost time (as they have done for recent breast cancer cohort as part of phase 1b preparation), and we see more women, (and perhaps the occasional unlucky male) signing up quickly for phase 1b cohorts in USA.

Hence perhaps the video last weekend, aimed I'm sure at those able to refer BC patients to Dr Tap et al.

Does that mean we are all waiting for AI suggested FUD?

- man alive, I suggest we move on to anther BB if so, as that's a most unhealthy situation.

FUD MONGERS need to BU2B USELESS.

I'm sure they'll travel in the holidays.

V-S She wants to be famous quickly.

Commuting between US-UK regularly, (even first class) with teenagers at home is the driver for her haste IMO.

B2HS2L

Posted in: AVCT

Posts: 5,092

Price: 44.25

No Opinion

RE: Recommended Dose for Expansion (RDE) cohort12 Dec 2024 08:56

CC - Surely time for an R&D spotlight series increment if news is hard to come by.

Just My 2c

+++

Glad you agree CC ha ha!

"A bid could come in 70-90p to buy us out. The avct bod recommend it ..."

Avacta board recommending it without a CFO's input?

That'll be why we don't currently have one I assume.

30.09.2024 - Investor Meet Presentation Q/A session:

Question 15:

You announced at the AGM that Tony was stepping down as CFO in October. Any news on when we’ll see a new CFO appointment?

Answer 15

Something we’ve been working very hard on, I’m pleased to say we’ve made very good progress, we’ve excellent candidates who have come through, we have seen both significant experience in biotech as well as in US capital markets and dealing with US specialist investors, we hope to be able to make an announcement over the next month or two.

Seems like they are reviewing individual applicants but, - perhaps it a plainer and simpler matter than that.

Avacta maybe saving the FCO position as collateral for a suitable BP to parachute their man into Avacta's board room.

Too good an opportunity to miss if the deal passes muster with CC / SB / SC ha ha.

Candidate needs to have the know how and experience to advise / assist on NASDAQ entry.

BP assisting Avacta enter NASDAQ? - Who'dathunkit

OOPS - That was a sarcoma advocacy group.